4th Annual ECD Medical Symposium Paris, France

Xavier Solanich, MD, PHD
Boulevard de l'Hôpita
Paris, France
April 1, 2016

Paris Medical Symposium Group Picture 2016

Symposium Summary

The Erdheim-Chester Disease Global Alliance is pleased to provide the following summary of presentations given at this year’s 4th Annual International ECD Medical Symposium, held on September 15, 2016, at Hôpital Pitié-Salpêtrière in Paris, France. The meeting allowed medical professionals to collaborate on ECD research, share medical findings, and discuss patient care. Thank you to this year’s co-host, Professor Julien Haroche, MD, PhD; to all presenters who shared their data and expertise during panel discussions; to all attendees interested in learning more about ECD; and to everyone involved in planning and making this event a success. A special thank you to the volunteers who created this summary for the community and for the professionals who were unable to attend.

Programs with Symposium Agenda

Presentations

The following presentations were given at the 2016 meeting. Visit the ECD Global Alliance YouTube channel for all published ECD related videos.

PresenterPresentation SlidesVideos
Prof. Julien Haroche, MD, PhDWelcomeWelcome
Omar Abdel-Wahab, MD, PhD and Benjamin Durham, MD;Insights into the Cell-of-Origin of the Histiocytoses Using Patient-­‐Derived Xenograft Murine ModelsInsights into the Cell-of-Origin of the Histiocytoses Using Patient-­‐Derived Xenograft Murine Models
Lorenzo Dagna, MD, PhDCCL18 in Erdheim-Chester Disease: Potential Implications in the PathogenesisNot available
Matthew Collin, MDThe Hematopoietic Origin of Adult HistiocytosisNot available
Matthias Papo, MDErdheim-Chester disease is frequently associated with myeloproliferative neoplasms and myelodysplastic syndromes: a systematic clinical and molecular series of 189 patientsNot available
Fleur Cohen-Aubart, MD & Wilfred Le Goff, MDMarked alteration of circulating immune cells in Erdheim-Chester disease in a large single-center series of 46 patientsNot available
Roei D. Mazor, MDBiopsy Specimens of Erdheim-Chester Disease PatientsNot available
Filip Janku, MD, PhDClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester DiseaseClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease
Tahla Munir, MDA Single- centre Experience of Treating Adult Patients with Langerhans' cell
Histiocytosis and Erdheim Chester Disease; Sustained Response to Oral Methotrexate in Frontline and Relapsed Disease		A Single- centre Experience of Treating Adult Patients with Langerhans' cellHistiocytosis and Erdheim Chester Disease; Sustained Response to Oral Methotrexate in Frontline and Relapsed Disease
Achille Aouba, MD, PhDSuperior Efficacy and Equivalent Safety of Double-dose Anakinra in Erdheim-Chester DiseaseSuperior Efficacy and Equivalent Safety of Double-dose Anakinra in Erdheim-Chester Disease
Tahla Munir, MDSingle Centre Experience of Treating Four Cases of Relapsed/Refractory BRAF Mutated Erdheim Chester Disease (ECD) / Langerhan’s Cell Histiocytosis(LCH) with Oral BRAF Inhibitor VemurafenibSingle Centre Experience of Treating Four Cases of Relapsed/Refractory BRAF Mutated Erdheim Chester Disease (ECD) / Langerhan’s Cell Histiocytosis(LCH) with Oral BRAF Inhibitor Vemurafenib
Fleur Cohen-Aubart, MD and Julien Haroche, MD, PhDThe LOVE trial: preliminary resultsNot available
Juvianee Estrada-Veras, MDDabrafenib and Trametinib as Potential Therapy in BRAF V600E Positive ErdheimChester Disease (ECD): Preliminary ResultsNot available
Eli L. Diamond, MDPhase 2 Trial of Single-Agent Cobimetinib for Adults with Histiocytic Disorders: Preliminary ResultsNot available
Tahla Munir, MDDabrafenib in combination with Trametinib is effective in treatment of refractory BRAF mutated mixed histiocytic disease- A Case reportDabrafenib in combination with Trametinib is effective in treatment of refractory BRAF mutated mixed histiocytic disease- A Case report
Diana Melo, MDSpectrum of Cardiovascular Involvement in Erdheim-Chester Disease Evaluated by Multimodality ImagingNot available
Mark Heaney, MD, Julien Haroche, MD, PhD, Eli L. Diamond, MD, Matthew Collin, MD, Lorenzo Dagna, MD, PhDPanel Discussion: ECD Patient Registry: Community Tool for ResearchPanel Discussion: ECD Patient Registry: Community Tool for Research
Augusto Vaglio, MD, PhD, Juvianee Estrada-Veras, MD, Filip Janku, MD, PhD, Omar Abdel-Wahab, MD, PhD, Javier Martin, MD, PhDPanel Discussion: Proposed ECD GWAS StudyPanel Discussion: Proposed ECD GWAS Study
Corrado Campochiaro, MDManagement of ECD Symptoms and Side Effects of TreatmentsManagement of ECD Symptoms and Side Effects of Treatments
Giulio Cavalli, MDAdult Onset (Infratentorial) Leukoencephalopathy as Presenting Manifestation of Erdheim-Chester DiseaseAdult Onset (Infratentorial) Leukoencephalopathy as Presenting Manifestation of Erdheim-Chester Disease
Carine Courtillot, MDEndocrine manifestations in Erdheim-Chester diseaseEndocrine manifestations in Erdheim-Chester disease
Benjamin Durham, MDInsights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Murine ModelsInsights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Murine Models
Marina Ferrarini, MDTailoring Treatment for Erdheim-Chester Disease: Focus on ECDTailoring Treatment for Erdheim-Chester Disease: Focus on ECD
Ronald Go, MDEfficacy of Cladribine (2-CdA) in the Treatment of Erdheim-Chester Disease (ECD)Efficacy of Cladribine (2-CdA) in the Treatment of Erdheim-Chester Disease (ECD)
Filip Janku, MD, PhDEncouraging activity of MEK inhibitor trametinib in patients with Erdheim-Chester disease irrespective of BRAF mutation statusClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester DiseaseEncouraging activity of MEK inhibitor trametinib in patients with Erdheim-Chester disease irrespective of BRAF mutation statusClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease
Javier Martin, MD, PhDFuture Genetic Studies in Erdheim-Chester disease – GWAS StudyFuture Genetic Studies in Erdheim-Chester disease – GWAS Study
Kenneth McClain, MD, PhDElevated CSF Osteopontin and Circulating Cells with BRAF Mutations in Patients with Langerhans Cell Histiocytosis-Associated Neurodegeneration -A Model for ECD?Elevated CSF Osteopontin and Circulating Cells with BRAF Mutations in Patients with Langerhans Cell Histiocytosis-Associated Neurodegeneration -A Model for ECD?
Augusto Vaglio, MD, PhDMRI evidence of cardiac involvement in Erdheim-Chester diseaseMRI evidence of cardiac involvement in Erdheim-Chester disease
Julien Haroche, MD, PhD & Kathleen BrewerClosingNot available